News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
181,884 Results
Type
Article (12822)
Company Profile (25)
Press Release (169037)
Section
Business (61902)
Career Advice (275)
Deals (11945)
Drug Delivery (37)
Drug Development (20991)
Employer Resources (39)
FDA (2613)
Job Trends (3798)
News (95316)
Policy (6918)
Tag
Academia (988)
Alliances (14949)
Alzheimer's disease (472)
Antibody-drug conjugate (ADC) (34)
Approvals (2624)
Artificial intelligence (53)
Bankruptcy (152)
Best Places to Work (2733)
Breast cancer (59)
Cancer (430)
Career advice (230)
Cell therapy (82)
Clinical research (16620)
Collaboration (169)
COVID-19 (734)
C-suite (44)
Cystic fibrosis (44)
Data (410)
Diabetes (38)
Diagnostics (1569)
Earnings (23472)
Events (17871)
Executive appointments (158)
FDA (2780)
Funding (407)
Gene therapy (61)
GLP-1 (180)
Government (1215)
Healthcare (5207)
Infectious disease (766)
Inflammatory bowel disease (37)
Interviews (37)
IPO (6416)
Job creations (1124)
Job search strategy (219)
Layoffs (171)
Legal (1563)
Lung cancer (43)
Manufacturing (71)
Medical device (3095)
Medtech (3097)
Mergers & acquisitions (5578)
Metabolic disorders (131)
Neuroscience (571)
NextGen Class of 2024 (2182)
Non-profit (2410)
Northern California (542)
Obesity (70)
Opinion (104)
Parkinson's disease (34)
Patents (40)
People (18135)
Phase I (5590)
Phase II (7925)
Phase III (4975)
Pipeline (284)
Policy (35)
Postmarket research (433)
Preclinical (2262)
Radiopharmaceuticals (78)
Rare diseases (89)
Real estate (1355)
Regulatory (4477)
Research institute (918)
Resumes & cover letters (45)
Series A (71)
Series B (49)
Southern California (489)
Startups (2976)
United States (4506)
Vaccines (145)
Weight loss (40)
Date
Today (53)
Last 7 days (204)
Last 30 days (749)
Last 365 days (11306)
2024 (11258)
2023 (12404)
2022 (16752)
2021 (16993)
2020 (16499)
2019 (13713)
2018 (10671)
2017 (10021)
2016 (8588)
2015 (10244)
2014 (7149)
2013 (5312)
2012 (5603)
2011 (6095)
2010 (5743)
Location
Africa (220)
Arizona (36)
Asia (10740)
Australia (1912)
California (1235)
Canada (636)
China (66)
Colorado (69)
Connecticut (62)
Europe (25331)
Florida (170)
Illinois (100)
Indiana (50)
Japan (36)
Maryland (167)
Massachusetts (903)
Minnesota (62)
New Jersey (309)
New York (389)
North Carolina (196)
Northern California (542)
Ohio (50)
Pennsylvania (259)
South America (265)
Southern California (489)
Texas (162)
Virginia (35)
Washington State (127)
181,884 Results for "novartis venture funds".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Layoffs
Novartis Cuts MorphoSys Sites in Boston, Munich, Affecting 330 Jobs
The closures follow Novartis’s acquisition of MorphyoSys earlier this year.
December 19, 2024
·
1 min read
·
Annalee Armstrong
Business
Novartis, Versant Launch RNA Kidney Medicines—Focused Borealis
Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the companies on Thursday launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases.
August 22, 2024
·
2 min read
·
Kate Goodwin
Press Releases
Niterra Ventures Company Invests $18M Additional Funding in Neoplas Med GmbH
November 25, 2024
·
4 min read
Legal
Novartis Loses Appeal to Bar Entresto Generic From U.S. Market
Novartis is seeking to prevent the entry of generics for its blockbuster heart failure drug Entresto, its top-selling asset that brought in more than $6 billion in net global sales last year.
December 5, 2024
·
2 min read
·
Tristan Manalac
Mergers & Acquisitions
Novartis CEO Promises More Deals of Up to $5B, With an Eye for Early Science
Novartis has disclosed roughly $19.4 billion in deals in the past five years. CEO Vas Narasimhan says there’s more to come.
November 21, 2024
·
2 min read
·
Annalee Armstrong
J.P. Morgan Raises Over $500M for First Biotech Venture Capital Fund
J.P. Morgan’s life sciences venture capital arm on Thursday announced it closed its first biotech fund, targeting companies in cardiometabolic disease, immunology, oncology and genetic medicine.
June 14, 2024
·
2 min read
·
Tyler Patchen
Radiopharma
Novartis Drops Up to $745M to Move Deeper Into Competitive Radiopharma Space
The deal has secured Novartis the chance to work with Ratio Therapeutics on a novel drug candidate that could fortify the Big Pharma against competition from would-be radiopharmaceutical rivals such as BMS and Lilly.
November 18, 2024
·
2 min read
·
Nick Paul Taylor
Mergers & acquisitions
Novartis Buys Kate Therapeutics, Eyeing $55B CGT Market Opportunity by 2030
Novartis’ up to $1.1 billion acquisition of gene therapy specialist Kate Therapeutics fits with the pharma’s plan to expand its new modality pipeline to ensure long-term business sustainability.
November 21, 2024
·
2 min read
·
Tristan Manalac
Pharm Country
Regeneron Launches $500M Venture Capital Fund Skewed Toward Biotech
While the VC fund launched on Monday by Regeneron Pharmaceuticals has an investment mandate that includes healthcare broadly, Regeneron Ventures will lean towards biotechnology, devices, tools and enabling technologies.
April 15, 2024
·
2 min read
·
Tyler Patchen
Earnings
Novartis Gets Q3 Beat on Strong Cosentyx Sales, But Pluvicto Disappoints
Novartis exceeded analyst expectations in the third quarter, driven primarily by the strong U.S. sales of Cosentyx, as well as the robust performances of Kesimpta and Kisqali.
October 29, 2024
·
2 min read
·
Tristan Manalac
1 of 18,189
Next
